ReviewCancer biology & therapy2020
Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression.
Review in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Imaging and Clinicopathological Features of Squamous Cell Metaplastic Breast Carcinoma: A 22-Case Retrospective Study.Journal of clinical medicine · 2026Article
- A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.Discover oncology · 2025Article
- HER2 positive primary breast squamous cell carcinoma with good prognosis: a case report.AME case reports · 2025Article
- Primary squamous cell carcinoma of the breast: a case report.Discover oncology · 2024Article
- A Case Report of a Rare ER+, PR- Pure Metaplastic Breast Squamous Cell Carcinoma with HER2 Overexpression.The American journal of case reports · 2023Article
- Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report.Frontiers in pharmacology · 2023Article
- Breast implant-associated squamous cell carcinoma in a male patient: A case report and review of the medical literature.Frontiers in surgery · 2022Article
- Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinicopathologic features and immunophenotype of primary squamous cell carcinoma of the breast (PSCCB) with HER2 overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.